These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 26462288)

  • 1. Sustained virological response and its treatment predictors in hepatitis C virus genotype 4 compared to genotypes 1, 2, and 3: a meta-analysis.
    Yee BE; Nguyen NH; Zhang B; Lin D; Vutien P; Wong CR; Lutchman GA; Nguyen MH
    BMJ Open Gastroenterol; 2015; 2(1):e000049. PubMed ID: 26462288
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sustained virologic response to standard interferon or pegylated interferon and ribavirin in patients with hepatitis C virus genotype 5: systematic review and meta-analysis of ten studies and 423 patients.
    Devaki P; Jencks D; Yee BE; Nguyen MH
    Hepatol Int; 2015 Jul; 9(3):431-7. PubMed ID: 26016464
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Meta-analysis: influence of host and viral factors in patients with chronic hepatitis C genotype 4 treated with pegylated interferon and ribavirin.
    Yee BE; Nguyen NH; Zhang B; Vutien P; Wong CR; Lutchman GA; Nguyen MH
    Eur J Gastroenterol Hepatol; 2014 Nov; 26(11):1189-201. PubMed ID: 25171028
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictive value of rapid virological response and early virological response on sustained virological response in HCV patients treated with pegylated interferon alpha-2a and ribavirin.
    Yu JW; Wang GQ; Sun LJ; Li XG; Li SC
    J Gastroenterol Hepatol; 2007 Jun; 22(6):832-6. PubMed ID: 17565637
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Peginterferon alpha-2a and ribavirin versus peginterferon alpha-2a monotherapy in early virological responders and peginterferon alpha-2a and ribavirin versus peginterferon alpha-2a, ribavirin and amantadine triple therapy in early virological nonresponders: the SMIEC II trial in naïve patients with chronic hepatitis C.
    Angelico M; Koehler-Horst B; Piccolo P; Angelico F; Gentile S; Francioso S; Tarquini P; Vecchia RD; Ponti L; Pilleri G; Barlattani A; Grieco A; Soccorsi F; Guarascio P; Demelia L; Sorbello O; Rossi Z; Forlini G; Zaru S; Bandiera F;
    Eur J Gastroenterol Hepatol; 2008 Jul; 20(7):680-7. PubMed ID: 18679072
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Meta-analysis: superior treatment response in Asian patients with hepatitis C virus genotype 6 versus genotype 1 with pegylated interferon and ribavirin.
    Nguyen NH; McCormack SA; Vutien P; Yee BE; Devaki P; Jencks D; Nguyen MH
    Intervirology; 2015; 58(1):27-34. PubMed ID: 25592813
    [TBL] [Abstract][Full Text] [Related]  

  • 7. OPERA: responses to peginterferon and ribavirin therapy in a subgroup of interferon-naïve patients with HIV/HCV genotype 2/3 co-infection in Italy.
    Bruno R; Cariti G; Nasta P; Capetti A; Ravasio V; Galli M; Raise E; Palmieri G; Iannacone C; Puoti M
    Liver Int; 2015 Jan; 35(1):120-9. PubMed ID: 25041136
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of pegylated interferon plus ribavirin therapy for chronic hepatitis C genotype 6: a meta-analysis.
    Wang X; Liu F; Wei F; Ren H; Hu H
    PLoS One; 2014; 9(6):e100128. PubMed ID: 24963667
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Meta-analysis of patients with hepatitis C virus genotype 6: 48 weeks with pegylated interferon and ribavirin is superior to 24 weeks.
    Nguyen NH; McCormack SA; Yee BE; Devaki P; Jencks D; Chao DT; Nguyen MH
    Hepatol Int; 2014 Oct; 8(4):540-9. PubMed ID: 26202759
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-efficacy analysis of peginterferon alfa-2b plus ribavirin compared with peginterferon alfa-2a plus ribavirin for the treatment of chronic hepatitis C.
    Malone DC; Tran TT; Poordad FF
    J Manag Care Pharm; 2005 Oct; 11(8):687-94. PubMed ID: 16194133
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sustained virological response rates to antiviral therapy in genotype 1 and 3 chronic hepatitis C patients: a study from north India.
    Gupta V; Kumar A; Sharma P; Tyagi P; Bansal N; Singla V; Arora A
    J Clin Exp Hepatol; 2014 Dec; 4(4):287-92. PubMed ID: 25755575
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictive value of early virologic response in HIV/hepatitis C virus-coinfected patients treated with an interferon-based regimen plus ribavirin.
    Laguno M; Larrousse M; Murillas J; Blanco JL; León A; Milinkovic A; Loncá M; Martinez E; Sánchez-Tapias JM; de Lazzari E; Gatell JM; Costa J; Mallolas J
    J Acquir Immune Defic Syndr; 2007 Feb; 44(2):174-8. PubMed ID: 17106276
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Present, old and future strategies for anti-HCV treatment in patients infected by genotype-1: estimation of the drug costs in the Calabria Region in the era of the directly acting antivirals.
    Strazzulla A; Costa C; Pisani V; De Maria V; Giancotti F; Di Salvo S; Parisi SG; Basso M; Franzetti MM; Marascio N; Liberto MC; Barreca GS; Lamberti AG; Zicca E; Postorino MC; Matera G; Focà A; Torti C
    BMC Infect Dis; 2014; 14 Suppl 5(Suppl 5):S3. PubMed ID: 25236374
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Open, randomized, multicentre italian trial on PEG-IFN plus ribavirin versus PEG-IFN monotherapy for chronic hepatitis C in HIV-coinfected patients on HAART.
    Cargnel A; Angeli E; Mainini A; Gubertini G; Giorgi R; Schiavini M; Duca P;
    Antivir Ther; 2005; 10(2):309-17. PubMed ID: 15865225
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictive factors of early and sustained responses to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b: amino acid substitutions in the core region and low-density lipoprotein cholesterol levels.
    Akuta N; Suzuki F; Kawamura Y; Yatsuji H; Sezaki H; Suzuki Y; Hosaka T; Kobayashi M; Kobayashi M; Arase Y; Ikeda K; Kumada H
    J Hepatol; 2007 Mar; 46(3):403-10. PubMed ID: 17126448
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic effectiveness of biosimilar standard interferon versus pegylated interferon for chronic hepatitis C genotypes 2 or 3.
    Vigani AG; Gonçales ES; Pavan MH; Genari F; Tozzo R; Lazarini MS; Fais V; Feltrin A; Gonçales NS; Gonçales FL
    Braz J Infect Dis; 2012; 16(3):232-6. PubMed ID: 22729189
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sustained virological response to pegylated interferon plus ribavirin leads to normalization of liver stiffness in hepatitis C virus-infected patients.
    Macías J; Rivero A; Cifuentes C; Camacho A; Neukam K; Rivero-Juárez A; Mira JA; Torre-Cisneros J; Gómez-Mateos J; Pineda JA
    Enferm Infecc Microbiol Clin; 2013; 31(7):424-9. PubMed ID: 23453582
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prediction of sustained virological response to combination therapy with pegylated interferon alfa and ribavirin in patients with genotype 3 chronic hepatitis C.
    Tohra SK; Taneja S; Ghosh S; Sharma BK; Duseja A; Dhiman RK; Das A; Chawla YK
    Dig Dis Sci; 2011 Aug; 56(8):2449-55. PubMed ID: 21706207
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Haematological support during peg-interferon therapy for HCV-infected haemophiliacs improves virological outcomes.
    Kevans D; Farrell G; Hopkins S; Mahmud N; White B; Norris S; Bergin C
    Haemophilia; 2007 Sep; 13(5):593-8. PubMed ID: 17880449
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pegylated interferon alpha-2a and -2b in combination with ribavirin in the treatment of chronic hepatitis C: a systematic review and economic evaluation.
    Shepherd J; Brodin H; Cave C; Waugh N; Price A; Gabbay J
    Health Technol Assess; 2004 Oct; 8(39):iii-iv, 1-125. PubMed ID: 15461877
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.